Animal Pharm is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Animal Pharm launches flagship state-of-the-industry report with Stonehaven

Animal Pharm and Stonehaven Consulting have collaborated again on a new animal health industry report.

The New World of Innovation in Animal Care 2019 is Animal Pharm's flagship report and provides an overview on the trends in animal health and nutrition. It shows how the top animal care companies are beginning to converge technologies in nutrition, diagnostics, vaccines and therapeutics.

This report also profiles the top 12 players across all aspects of animal care and includes a 10-year outlook to describe how we see the market evolving.

For more information regarding the report and to download a free sample, click here.

Animal Pharm publishes many one-off reports. Most recently these have focused on microbiome health, digital technologies, the Latin American market, veterinary vaccines, antibiotic replacements and the top 50 animal health industry ranking. For more information on these titles contact:

Animal Pharm and Stonehaven Consulting also recently highlighted the leading start-up companies in the animal health space.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts